Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA

Core Insights - Sonoma Pharmaceuticals, Inc. has successfully registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA) [1] - This registration allows Sonoma to expand its regulatory footprint, enabling the company to manufacture and commercialize Microcyn technology products as cosmetics in the United States [1] Company Developments - The registration under MoCRA signifies a strategic move for Sonoma Pharmaceuticals to enhance its product offerings in the cosmetics market [1] - The Microcyn technology-based products are positioned to leverage the growing demand for innovative cosmetic solutions [1]